Patent Issued for Siglec transgenic mice and methods of use thereof (USPTO 12004494).

A patent has been issued to Alector LLC for Siglec transgenic mice and methods of use. Siglec proteins are a type of transmembrane protein expressed on immune and hematopoietic cells. These proteins are involved in immune system function and have been implicated in various human diseases. The patent describes the development of transgenic mice that express multiple human Siglec genes, which can be used to study the functions and interactions of these proteins in vivo and to test potential therapies targeting Siglec proteins. The mice can also serve as disease models for conditions such as Alzheimer's disease and cancer. [Extracted from the article]